CTIS2023-506838-68-00招募中1 期
A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants with RCC (KEYMAKER-U03): Substudy 03A - MK-3475-03A
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 267
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Has a histologically confirmed diagnosis of locally advanced/metastatic clear cell renal cell carcinoma (ccRCC), Has received no prior systemic therapy for advanced RCC; prior neoadjuvant/adjuvant therapy for RCC is acceptable if completed =12 months before randomization/allocation., Is able to swallow oral medication, Has adequate organ function, Participants receiving bone resorptive therapy must have therapy initiated at least 2 weeks before randomization/allocation, Has resolution of toxic effects of the most recent prior therapy to =Grade 1, Has adequately controlled blood pressure (BP =150/90 mm Hg) with no change in hypertensive medications within 1 week before randomization/allocation, Male participants are abstinent from heterosexual intercourse or agree to use contraception during treatment with and for at least 7 days after the last dose of lenvatinib and /or belzutifan; 7 days after lenvatinib and/or belzutifan is stopped, if the participant is only receiving pembrolizumab, pembrolizumab/quavonlimab, favezelimab/pembrolizumab, vibostolimab/pembrolizumab or a combination of the aforementioned drugs, no contraception is needed, Female participants must not be pregnant and not be a woman of childbearing potential (WOCBP) or is a WOCBP abstinent from heterosexual intercourse or using contraception during the intervention period and for at least 120 days after the last dose of pembrolizumab, pembrolizumab/quavonlimab, favezelimab/pembrolizumab, and vibostolimab/pembrolizumab, for 30 days after the last dose of lenvatinib or belzutifan, whichever occurs last and must abstain from breastfeeding during the study intervention period and for at least 120 days after study intervention
排除标准
- •Has urine protein =1 g/24 hours and has any of the following: (a) a pulse oximeter reading <92% at rest, or (b) requires intermittent supplemental oxygen, or (c) requires chronic supplemental oxygen (d) active hemoptysis within 3 weeks prior to the first dose of study intervention, Has received more than 4 previous systemic anticancer treatment regimens, Has a diagnosis of immunodeficiency or is receiving any form of immunosuppressive therapy within 7 days prior to the first dose of study intervention, Has known additional malignancy that is progressing or has required active treatment within the past 3 years, Has known central nervous system (CNS) metastases and/or carcinomatous meningitis, Has an active autoimmune disease that has required systemic treatment in the past 2 years; replacement therapy is not considered a form of systemic treatment and is allowed, Has an active infection requiring systemic therapy, Has a known history of human immunodeficiency virus (HIV) infection, Has a known history of Hepatitis B, Has had an allogenic tissue/solid organ transplant, Has clinically significant cardiovascular disease within 12 months from the first dose of study intervention administration, Has had major surgery within 3 weeks before first dose of study interventions, Has a history of lung disease, Has a history of inflammatory bowel disease, Has preexisting gastrointestinal (GI) or non-GI fistula, Has malabsorption due to prior GI surgery or disease, Has received prior radiotherapy within 2 weeks of start of study intervention, Has received a live or live attenuated vaccine within 30 days before the first dose of study drug; killed vaccines are allowed
研究者
相似试验
尚未招募
2 期
A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants with RCC (KEYMAKER-U03): Substudy 03ANL-OMON56282Merck Sharp & Dohme (MSD)5
招募中
1 期
A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants with RCC (U03): Sub study 03BMedDRA version: 21.1Level: PTClassification code: 10067946Term: Renal cell carcinoma Class: 100000004864Renal cell carcinomaCTIS2023-506839-15-00Merck Sharp & Dohme LLC244
进行中（未招募）
1 期
A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants with RCC (U03): Substudy 03BRenal Cell CarcinomaMedDRA version: 20.0Level: LLTClassification code 10038409Term: Renal cell carcinoma NOSSystem Organ Class: 100000004864EUCTR2019-003610-13-HUMerck Sharp & Dohme LLC370
进行中（未招募）
1 期
A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants with RCC (U03): Substudy 03ARenal Cell CarcinomaEUCTR2019-003609-84-FRMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc430
招募中
2 期
A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants With RCC (KEYMAKER-U03): Substudy 03BNL-OMON55940Merck Sharp & Dohme (MSD)9